MARKET

BTAI

BTAI

Bioxcel Therapeutics Inc
NASDAQ
1.430
-0.050
-3.38%
Closed 17:34 05/13 EDT
OPEN
1.480
PREV CLOSE
1.480
HIGH
1.510
LOW
1.354
VOLUME
229.75K
TURNOVER
--
52 WEEK HIGH
36.64
52 WEEK LOW
1.290
MARKET CAP
7.82M
P/E (TTM)
-0.0608
1D
5D
1M
3M
1Y
5Y
1D
Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI)
TipRanks · 19h ago
BioXcel Therapeutics Advances Clinical Trials Amid Financial Adjustments
TipRanks · 1d ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
NASDAQ · 1d ago
*BioXcel Therapeutics 1Q Rev $168,000 >BTAI
Dow Jones · 1d ago
*BioXcel Therapeutics 1Q Loss $7.25M >BTAI
Dow Jones · 1d ago
*BioXcel Therapeutics 1Q Loss/Shr $1.50 >BTAI
Dow Jones · 1d ago
Weekly Report: what happened at BTAI last week (0505-0509)?
Weekly Report · 1d ago
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Barchart · 2d ago
More
About BTAI
More
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Recently
Symbol
Price
%Change

Webull offers BioXcel Therapeutics Inc stock information, including NASDAQ: BTAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BTAI stock methods without spending real money on the virtual paper trading platform.